Fairvalue-Calculator Fairvalue-Calculator
EN DE

NanoGroup S.A (NNG) Fair Value & Analysis

Healthcare · PL · Market cap 98.5M PLN

Price2.31 PLN
Fair Value1.60 PLN
Upside-30.7%
Quality86/100
Evidence: Low Range 1.20 PLN – 2.01 PLN

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

NanoGroup S.A (NNG) currently trades at 2.31 PLN, while our model-based Fair Value estimate is 1.60 PLN — implying the stock looks roughly 30.7% overvalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

NanoGroup S.A. operates as a biotechnology company in Poland. It engages in the production of medicines and other pharmaceutical products, and research and development work in the field of biotechnology and other natural and technical sciences. The company is also involved in technical research and analysis. In addition, it manages a portfolio of companies that manage projects to meet the needs of modern medicine in the field of oncology and transplantology. The company was founded in 2016 and is based in Warsaw, Poland.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is NanoGroup S.A (NNG) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1.60 PLN versus a price of 2.31 PLN — about −31% (overvalued). Model-based estimate, not financial advice.
What is the fair value of NNG?
Our 21-model fair value for NanoGroup S.A is 1.60 PLN (as of Jun 24, 2026), built from audited fundamentals. The current price is 2.31 PLN.
What is the quality score of NNG?
NanoGroup S.A has a Quality Score of 86/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.